Ray A, Cohn L
Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, 105 LCI, New Haven, CT 06520-8057, USA.
Curr Opin Investig Drugs. 2000 Dec;1(4):442-8.
The identification of distinct T helper (Th)-cell subsets that differ in cytokine production and effector functions not only provides a framework for normal immune responses to infection and injury, but also for many disease processes. Studies in both humans and animals indicate that airway inflammation in allergic asthma is orchestrated by CD4+ Th2-cells that secrete the cytokines IL-4, IL-5 and IL-13. Many studies also suggest that IFN gamma, secreted by Th1-cells, suppresses the development and effector functions of Th2-cells. Cross-regulation of Th1/Th2 responses has been demonstrated in many experimental systems including models of allergic inflammation/asthma. A challenging concept that has evolved as a result is the use of therapeutic modalities that will modulate the Th1/Th2 balance in asthma without deleterious side effects. In the clinical trial arena, the unmet challenging goal remains to convert the concept of Th1/Th2 balance modulation, without deleterious side effects, into clinical practice for the management of asthmatic disease.
不同辅助性T（Th）细胞亚群在细胞因子产生和效应功能方面存在差异，这一发现不仅为机体对感染和损伤的正常免疫反应提供了一个框架，也为许多疾病进程提供了框架。对人类和动物的研究表明，过敏性哮喘中的气道炎症是由分泌细胞因子白细胞介素-4（IL-4）、白细胞介素-5（IL-5）和白细胞介素-13（IL-13）的CD4 + Th2细胞所调控。许多研究还表明，Th1细胞分泌的干扰素γ（IFNγ）可抑制Th2细胞的发育和效应功能。在包括变应性炎症/哮喘模型在内的许多实验系统中，已证实Th1/Th2反应存在交叉调节。由此产生的一个具有挑战性的概念是使用治疗方法来调节哮喘中的Th1/Th2平衡而不产生有害副作用。在临床试验领域，尚未实现的具有挑战性的目标仍然是将无有害副作用的Th1/Th2平衡调节概念转化为哮喘疾病管理的临床实践。
